DE60320784D1 - Stände zur modulierung des knochenwachstums - Google Patents

Stände zur modulierung des knochenwachstums

Info

Publication number
DE60320784D1
DE60320784D1 DE60320784T DE60320784T DE60320784D1 DE 60320784 D1 DE60320784 D1 DE 60320784D1 DE 60320784 T DE60320784 T DE 60320784T DE 60320784 T DE60320784 T DE 60320784T DE 60320784 D1 DE60320784 D1 DE 60320784D1
Authority
DE
Germany
Prior art keywords
bone growth
stands
bone
modulating
modulating bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60320784T
Other languages
English (en)
Inventor
Itai Bab
Raphael Mechoulam
Esther Shohami
Andreas Zimmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of DE60320784D1 publication Critical patent/DE60320784D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60320784T 2002-06-06 2003-06-08 Stände zur modulierung des knochenwachstums Expired - Lifetime DE60320784D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38588102P 2002-06-06 2002-06-06
US41027602P 2002-09-13 2002-09-13
PCT/IL2003/000480 WO2004103410A1 (en) 2002-06-06 2003-06-08 Methods compositions and articles of manufacture for modulating bone growth

Publications (1)

Publication Number Publication Date
DE60320784D1 true DE60320784D1 (de) 2008-06-19

Family

ID=33479219

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60320784T Expired - Lifetime DE60320784D1 (de) 2002-06-06 2003-06-08 Stände zur modulierung des knochenwachstums

Country Status (7)

Country Link
US (2) US7749953B2 (de)
EP (1) EP1509250B1 (de)
JP (1) JP2006517194A (de)
AT (1) ATE394124T1 (de)
AU (1) AU2003233172A1 (de)
DE (1) DE60320784D1 (de)
WO (1) WO2004103410A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7024027B1 (en) * 2001-11-13 2006-04-04 Koninklijke Philips Electronics N.V. Method and apparatus for three-dimensional filtering of angiographic volume data
JP2006517194A (ja) * 2002-06-06 2006-07-20 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 骨成長を調節するための方法、組成物および製造物
CN1747926A (zh) * 2002-12-19 2006-03-15 麦克公司 取代酰胺化合物
US7407753B2 (en) 2004-05-24 2008-08-05 Yissum Research Development Company Of The Hebrewuniversityofjerusalem Methods, kits and pharmaceutical compositions for diagnosing, delaying onset of, preventing and/or treating osteoporosis
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
US20100004244A1 (en) * 2006-06-27 2010-01-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of cb2 receptor agonists for promoting neurogenesis
WO2008033501A2 (en) * 2006-09-14 2008-03-20 Spineology, Inc. Absorbent fabric implant
JP5829400B2 (ja) * 2008-01-24 2015-12-09 レメドー バイオメッド リミテッド 骨再生のためのエリスロポイエチンおよびフィブロネクチン組成物
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
US9428431B2 (en) 2008-10-06 2016-08-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions comprising CB receptor agonists, uses thereof and methods for their preparation
TWI443337B (zh) * 2008-10-10 2014-07-01 Ct Hospitalier Universitaire Sainte Justine 用於脊柱側彎之分類及診斷的方法
US8541386B2 (en) * 2009-08-19 2013-09-24 University Of South Florida Cannabinoid 2 (CB2) receptor gene promoter and unique RNA transcripts in B cells and methods of use
WO2016080813A1 (en) * 2014-11-21 2016-05-26 Samsung Electronics Co., Ltd. Method and apparatus for processing medical image
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
KR102002817B1 (ko) * 2017-10-25 2019-07-23 주식회사 시티오브테크 방수 아스콘 첨가제 및 그 제조방법, 방수 아스콘 및 그 제조방법 그리고, 방수 아스콘 시공방법
WO2019232413A1 (en) * 2018-05-31 2019-12-05 Corbus Pharmaceuticals Inc. Cannabinoids and uses thereof
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization
KR20220138990A (ko) * 2021-04-07 2022-10-14 주식회사 스템바이오 우유 유래 세포외소포체를 포함하는 골형성 촉진용 조성물
CN114748604B (zh) * 2022-05-10 2023-04-07 四川大学 一种用于骨髓损伤和/或抑制的复合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068234A (en) 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
US5225925A (en) 1991-01-23 1993-07-06 Amoco Corporation Sensitized erbium fiber optical amplifier and source
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
EP0499242B1 (de) 1991-02-15 1996-06-26 Takeda Chemical Industries, Ltd. Mit einem Zellwachstumsfaktor bewirkte Anregung von Wachstum im Knocheninneren
FR2673852B1 (fr) 1991-03-13 1994-04-15 Labinal Precision Mecanique Perfectionnements apportes aux cartouches de filtration comprenant un element filtrant constitue par une feuille plissee.
IL101927A0 (en) 1992-05-19 1992-12-30 Yissum Res Dev Co Probe for cannabinoid receptors
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US6352972B1 (en) 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US6352973B1 (en) 1995-06-07 2002-03-05 Osteopharm Inc. Bone stimulating factor
US6008208A (en) 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6440421B1 (en) 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5688825A (en) 1996-05-31 1997-11-18 University Of Connecticut Anandamide amidase inhibitors as analgesic agents
WO1998031227A1 (en) * 1997-01-21 1998-07-23 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE19706903A1 (de) 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
WO1998041519A1 (en) * 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
WO1999026612A1 (en) * 1997-11-21 1999-06-03 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
AU765670B2 (en) 1998-04-03 2003-09-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic endogenous cannabinoids analogues and uses thereof
ES2224658T3 (es) 1998-05-04 2005-03-01 The University Of Connecticut Nuevos canabinoides selectivos hacia el receptor cb2.
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
AU4013500A (en) 1999-07-28 2001-02-19 Ewonders.Com Dynamic data gathering markup language
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
DE60106026T2 (de) 2000-06-23 2006-02-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions
US20020111377A1 (en) 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
JP5093967B2 (ja) * 2001-04-06 2012-12-12 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 睡眠時の自律的安定性に関するカンナビノイドの機能的役割
JP2006517194A (ja) * 2002-06-06 2006-07-20 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 骨成長を調節するための方法、組成物および製造物
EP1606019A1 (de) * 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Inverse agonisten und neutrale antagonisten des cannabinoid-rezeptors als arzneimittel zur behandlung von knochenkrankheiten

Also Published As

Publication number Publication date
US20050137159A1 (en) 2005-06-23
EP1509250A1 (de) 2005-03-02
AU2003233172A1 (en) 2004-12-13
WO2004103410A1 (en) 2004-12-02
US20100222438A1 (en) 2010-09-02
JP2006517194A (ja) 2006-07-20
ATE394124T1 (de) 2008-05-15
EP1509250A4 (de) 2005-08-17
US7749953B2 (en) 2010-07-06
EP1509250B1 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
DE60320784D1 (de) Stände zur modulierung des knochenwachstums
GEP20074078B (en) Fluoro substituted cyclo-alkanoindoles, compositions comprising them and their use
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
BR0011172A (pt) Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2
EP1474687A4 (de) Marks als modifikatoren des p53-pfades und anwendungsverfahren
UY27362A1 (es) Métodos de usar inhibidores de epóxido hidrolasa soluble
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
BRPI0414598A (pt) indóis substituìdos
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
NO20056161L (no) Formuleringer for behandling av artrittilstander
WO2003103581A3 (en) COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
DE60142031D1 (de) Viskoelastische substanzen zur verwendung bei mittelohr operationen
RS20070095A (en) Alkyliden-tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents
DE60230990D1 (de) Zellkulturmethode zur erzeugung von prostata-ähnlichen acini
DE60112742D1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE489974T1 (de) Isoliertes naturidentisches kollagen
MY138550A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
TR200200278T2 (tr) Kalsilitik bileşimler
EA200501557A1 (ru) Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла

Legal Events

Date Code Title Description
8364 No opposition during term of opposition